Vonoprazan/amoxicillin explained
| Type: | combo |
| Component1: | Vonoprazan |
| Class1: | Potassium-competitive acid blocker |
| Component2: | Amoxicillin |
| Class2: | Beta-lactam antibiotic |
| Tradename: | Voquezna Dual Pak |
| Dailymedid: | Voquezna |
| Routes Of Administration: | By mouth |
| Atc Prefix: | A02 |
| Atc Suffix: | BD17 |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection. It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic. It is taken by mouth.
The co-packaged medication was approved for medical use in the United States in May 2022.[2] [3] [4]
Medical uses
Vonoprazan/amoxicillin is indicated for the treatment of H. pylori infection in adults.[5]
Research
The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment of H. pylori infection[6] and also compared with the triple therapy of using vonoprazan, amoxicillin, and clarithromycin for the eradication of H. pylori infection.[7] Both treatments have been found to be effective. evidence indicates that vonoprazan/amoxicillin therapy has similar efficacy to bismuth-containing quadruple therapies in eliminating H. pylori.[8]
Notes and References
- Web site: Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit . DailyMed . 21 June 2022 . 3 July 2022 . 3 July 2022 . https://web.archive.org/web/20220703054730/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 . live .
- Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults . Phathom Pharmaceuticals . GlobeNewswire . 3 May 2022 . 9 May 2022 . 10 May 2022 . https://web.archive.org/web/20220510034341/https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html . live .
- Web site: Voquezna Dual Pak (amoxicillin and vonoprazan) FDA Approval History. Drugs.com. 16 May 2022. 16 May 2022. https://web.archive.org/web/20220516040849/https://www.drugs.com/history/voquezna-dual-pak.html. live.
- Web site: FDA NDA approval . U.S. Food and Drug Administration (FDA) . 12 May 2022 . 12 May 2022 . https://web.archive.org/web/20220512000404/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf . live .
- Web site: Voquezna Dual Pak (vonoprazan/amoxicillin) monograph . Medscape . 5 May 2022 . 11 May 2022 . 11 May 2022 . https://web.archive.org/web/20220511232203/https://reference.medscape.com/drug/voquezna-dual-pak-vonoprazan-amoxicillin-4000290 . live .
- Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K . Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan . Gut . 69 . 6 . 1019–1026 . June 2020 . 31915235 . 7282559 . 10.1136/gutjnl-2019-319954 .
- Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K . Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori . Digestion . 101 . 6 . 743–751 . November 2020 . 31434101 . 10.1159/000502287 . 201277349 .
- Pai L, Patil S, Liu S, Wen F . A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance . Front Cell Infect Microbiol . 13 . 1327069 . 2023 . 38188636 . 10770264 . 10.3389/fcimb.2023.1327069 . free .
